Rahaf Mahmoud Altahan

Dr. Rahaf Mahmoud Altahan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
RARahaf Mahmoud Altahan
Rahaf Mahmoud Altahan
NMNatalie Mathews
Natalie Mathews
ABAlex Bourguignon
Alex Bourguignon
STSubia Tasneem
Subia Tasneem
DADonald M. Arnold
Donald M. Arnold
CHCatherine P. M. Hayward
Catherine P. M. Hayward
Introduction: Light transmission aggregometry (LTA) is important for diagnosing platelet function disorders (PFD) and von Willebrand disease (VWD) affecting ristocetin‐induced platelet aggregation (RIPA). Nonetheless, data is lacking on the utility of LTA for investigating thrombocytopenic patients and platelet rich plasma samples with low platelet counts (L‐PRP). Previously, we developed a strategy for diagnostic LTA assessment of L‐PRP that included: (1) acceptance of referrals/samples, regardless of thrombocytopenia severity, (2) tailored agonist selection, based on which are informative for L‐PRP with mildly or severely low platelet counts, and (3) interpretation of maximal aggregation (MA) using regression‐derived 95% confidence intervals, determined for diluted control L‐PRP (C‐L‐PRP).Methods: To further evaluate the L‐PRP LTA strategy, we evaluated findings for a subsequent patient cohort.Results: Between 2008 and 2021, the L‐PRP strategy was applied to 211 samples (11.7% of all LTA samples) from 192 unique patients, whose platelet counts (median [range] × 109/L) for blood and L‐PRP were: 105 [13–282; 89% with thrombocytopenia] and 164 [17–249], respectively. Patient‐L‐PRP had more abnormal MA findings than simultaneously tested C‐L‐PRP (p‐values <0.001). Among patients with accessible electronic medical records (n = 181), L‐PRP LTA uncovered significant aggregation abnormalities in 45 (24.9%), including 18/30 (60%) with <80 × 109 platelets/L L‐PRP, and ruled out PFD, and VWD affecting RIPA, in others. The L‐PRP LTA strategy helped diagnose VWD affecting RIPA, Bernard Soulier syndrome, familial platelet disorder with myeloid malignancy, suspected ITGA2B/ITGB3‐related thrombocytopenia, and acquired PFD.Conclusion: Diagnostic LTA with L‐PRP, using a strategy that considers thrombocytopenia severity, is feasible and informative.

6 July 2023 in Clinical Case Reports
Verified
Journal Article
Open access
MBMohammed A. Bafail
Mohammed A. Bafail
RARahaf Mahmoud Altahan
Rahaf Mahmoud Altahan
MSManar A. Samman
Manar A. Samman
STSuha A. Tashkandi
Suha A. Tashkandi
IMIbraheem H. Motabi
Ibraheem H. Motabi
AZAbdul Ali A Peer Zada
Abdul Ali A Peer Zada
Key Clinical Message: Complete molecular remission in a “variant APL” patient with short isoform of PML‐RARα and FLT3‐ITD mutation was achieved in response to ATRA and ATO plus IDA instead of standard treatment protocol. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy experienced in in patients with FLT3‐ITD. FLT3‐ITD mutations are the most common activating mutations in FLT3 gene, occurring in about 12 to 38% of acute promyelocytic leukemia cases, and are mainly associated with high white blood cell counts and poor clinical outcomes. Here, we present a case of APL variant with adverse prognostic features who showed short isoform [bcr3] of PML‐RARα and FLT3‐ITD mutation at diagnosis. The patient received all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) instead of standard treatment protocol, and achieved a complete morphological, cytogenetic and molecular response. However, the patient experienced differentiation syndrome, and coagulopathy that was subsequently resolved by continuous oxygen therapy, dexamethasone, and enoxaparin. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy in patients with FLT3‐ITD mutation.

30 July 2019 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
RARahaf Mahmoud Altahan
Rahaf Mahmoud Altahan
AMAreej Al Mugairi
Areej Al Mugairi
We present images (Figure 1A‐D) of a preterm girl who had severe anemia due to HDFN caused by maternal anti‐C and anti‐D alloantibodies. These images show erythrophagocytosis, which is a very interesting and rarely encountered feature. We believe that physicians taking care of such patients should be more aware of this characteristic yet under‐detected finding.

13 December 2023 in Clinical Case Reports
Verified
Journal Article
Open access
RARahaf Mahmoud Altahan
Rahaf Mahmoud Altahan
MAMohammed Lafi Alanazi
Mohammed Lafi Alanazi
MAMohammed Abdulaziz Alharbi
Mohammed Abdulaziz Alharbi
SASalman Almalki
Salman Almalki
AAAziza Alswayyed
Aziza Alswayyed
LALaila Alsuhaibani
Laila Alsuhaibani
Key Clinical Message: We present an interesting case that showed a non‐hematopoietic structure embedded in the bone marrow biopsy. Given the clinical and morphological difficulties, it was challenging to identify this artifact's nature. Publishing this case would familiarize pathologists with this artifact and save additional testing and delays in reporting.

10 February 2019 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
RARahaf Mahmoud Altahan
Rahaf Mahmoud Altahan
SAShatha Altahan
Shatha Altahan
SKSalem Khalil
Salem Khalil
Key Clinical Message: t(11;17) is a rare but recognized finding usually found in Acute Promyelocytic Leukemia with variant RARA translocation (APLv). We present a case of Acute Myeloid Leukemia with t(11;17) that has different break points than those occurring in APLv. The diagnosis of acute myeloid leukemia, not otherwise specified, acute monoblastic leukemia was reached after a thorough investigation. Reaching the correct diagnosis and distinguishing these two entities are essential as they have different management, prognosis, and overall survival.

11 November 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
RARahaf Mahmoud Altahan
Rahaf Mahmoud Altahan
Platelets are essential to primary hemostasis, and defects in their number or function can lead to clinically significant bleeding or thrombosis. Acquired platelet disorders are far more common than the inherited forms and arise in a wide range of settings, including drug exposure, autoimmune, systemic, and critical illnesses. This review examines current understanding of the mechanisms driving acquired platelet dysfunction and outlines the diagnostic and therapeutic approaches that are shaping contemporary standards of care. Drug-related and immune-mediated platelet defects remain the most recognized causes in clinical practice. Nevertheless, increasing evidence points to inflammation, particularly the profound dysregulation seen in sepsis, as a major contributor to abnormal platelet behavior. Although sepsis-associated platelet defects are frequent in practice and correlate with organ injury and adverse outcomes, they are rarely acknowledged in traditional frameworks of “acquired platelet disorders,” which tend to focus on classic hematologic and pharmacologic causes. This review summarizes current evidence on acquired platelet disorders and emphasizes the clinical and pathophysiologic relevance of sepsis-induced platelet dysfunction.